Systemic Allergic Reactions and Anaphylaxis Associated with Allergen Immunotherapy - 23/11/21
, Tolly E.G. Epstein, MD, MS a, b, David I. Bernstein, MD aRésumé |
Subcutaneous allergen immunotherapy (SCIT) is a proven treatment of allergic rhinitis, asthma, atopic dermatitis, and prevention of Hymenoptera venom anaphylaxis. The known benefit of SCIT, however, must be considered in each patient relative to the potential risks of systemic allergic reactions (SRs). A mean of 1 SR per 1000 injection visits (0.1%) was estimated to occur between 2008 and 2018. Life-threatening anaphylactic events are estimated to occur in 1/160,000 injection visits. The factors that contribute to SRs and fatal reactions (FRs) are reviewed. Risk management strategies are proposed to prevent and decrease future SCIT associated with SRs, anaphylaxis, and FR.
Le texte complet de cet article est disponible en PDF.Keywords : Allergen immunotherapy, Subcutaneous immunotherapy, Sublingual immunotherapy, Systemic reactions, Anaphylaxis
Plan
Vol 42 - N° 1
P. 105-119 - février 2022 Retour au numéro
Article précédent
- Recognition and Management of Food Allergy and Anaphylaxis in the School and Community Setting
- Susan Waserman, Anita Shah, Heather Cruickshank, Ernie Avilla
- Anaphylaxis to Drugs, Biological Agents, and Vaccines
- Ruchi H. Shah, Margaret M. Kuder, David M. Lang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?